Business Context and Reporting Period
This Form 6-K filing by SciSparc Ltd. covers the month of September 2025, with the report dated September 25, 2025. The company, headquartered in Tel Aviv, Israel, operates in the technology sector with a focus on AI and quantum computing applications for drug discovery.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
- Management Restructuring: Effective September 21, 2025, the Board resolved to swap leadership roles. Mr. Amitay Weiss, the former Chairman, was appointed President. Mr. Itschak Shrem, the former President, was appointed Chairman of the Board.
- Strategic Initiative: On September 25, 2025, the Company announced the launch of a new initiative utilizing quantum computing for 3D protein modeling to advance AI-driven drug discovery.
Guidance, Outlook, and Risks
The filing highlights a strategic pivot toward quantum computing-enabled protein modeling as a core initiative to revolutionize AI drug discovery. No specific financial guidance, quantitative outlook, or detailed risk factors were disclosed in this specific text. The filing incorporates a press release (Exhibit 99.1) for further details on the new initiative.
Investor Verification Checklist
- Verify the specific terms and compensation implications of the leadership swap between Mr. Weiss and Mr. Shrem.
- Review the full text of the September 25, 2025 press release (Exhibit 99.1) to understand the technical scope and timeline of the quantum computing initiative.
- Confirm if this strategic shift requires additional capital expenditure or changes to the company's existing R&D budget.
- Check subsequent filings for any impact of these changes on the company's operational roadmap or partnership agreements.